Meconium Aspiration Syndrome (MAS)

1. Clinical Overview

Definition and Importance

Meconium Aspiration Syndrome (MAS) is a severe respiratory disorder occurring in newborns who have inhaled meconium-stained amniotic fluid (MSAF) before, during, or immediately after birth, resulting in respiratory distress with characteristic radiographic changes in the absence of other identifiable causes. [1] It represents a complex pathophysiological process involving mechanical airway obstruction, chemical pneumonitis, and surfactant inactivation, with persistent pulmonary hypertension of the newborn (PPHN) as its most dangerous complication. [2]

MAS remains a significant cause of neonatal morbidity and mortality worldwide. Despite declining incidence in developed countries due to improved obstetric surveillance and avoidance of post-term deliveries, MAS continues to account for approximately 2% of neonatal intensive care admissions and carries a mortality rate of 5-12% in severe cases, primarily attributable to refractory PPHN. [3,4]

Key Clinical Messages

• Prevention is Primary: Active management of labour with appropriate intrapartum monitoring and avoidance of post-term pregnancy (> 41 weeks) has significantly reduced MAS incidence. [5]
• Delivery Room Management Has Changed: Current NRP guidelines (2020) no longer recommend routine tracheal suctioning even for non-vigorous infants born through MSAF. [6]
• Triple Pathophysiology: Understanding the "Triple Hit" (obstruction, chemical pneumonitis, surfactant inactivation) is essential for rational management. [7]
• PPHN is the Killer: Approximately 15-20% of MAS infants develop PPHN, which accounts for the majority of mortality. [8]
• ECMO Has Excellent Outcomes: MAS has the highest ECMO survival rate (approximately 94%) of all neonatal indications. [9]

Clinical Pearls

The Ball-Valve Effect: Meconium causes partial airway obstruction creating a ball-valve mechanism—air enters during inspiration when airways dilate but becomes trapped during expiration when airways narrow. This leads to progressive hyperinflation and predisposes to pneumothorax, which occurs in 15-33% of ventilated MAS infants. [10]

The Honeymoon Period: Infants may appear stable initially, then deteriorate significantly at 12-24 hours as chemical pneumonitis evolves. Any infant with respiratory symptoms following MSAF exposure should be observed for minimum 24 hours before discharge consideration. [11]

Differential Cyanosis = PPHN: A pre-ductal (right hand) to post-ductal (foot) saturation difference of > 10% indicates significant right-to-left shunting through the ductus arteriosus and should trigger immediate evaluation for PPHN and consideration of inhaled nitric oxide. [8]

Meconium ≠ MAS: Only 5% of infants born through MSAF develop MAS. The presence of meconium staining alone does not mandate intervention beyond careful observation. [3]

---

2. Epidemiology

Incidence and Prevalence

Meconium-stained amniotic fluid complicates 10-15% of all deliveries beyond 37 weeks gestation, increasing to 23-52% at ≥42 weeks. [3,12] Of these infants, approximately 5% develop MAS, with 30-50% of MAS cases requiring mechanical ventilation. [1]

Temporal Trends

The incidence of MAS has declined significantly over the past three decades from approximately 5-6% to 0.2-0.4% of live births in developed countries. [5,13] This reduction is attributed to:

1. Reduced post-term deliveries: Policy changes recommending induction at 41 weeks
2. Improved intrapartum monitoring: Earlier detection of fetal distress
3. Abandonment of amnioinfusion: Recognition that amnioinfusion does not prevent MAS
4. Changed resuscitation practices: Stopping ineffective routine tracheal suctioning

Risk Factors

Maternal and Obstetric Factors

Fetal Factors

The Post-Term Physiology

Post-term pregnancy (> 42 weeks) represents the highest-risk state for MAS due to converging physiological changes: [12]

1. Motilin Surge: Gut hormone motilin peaks at 41-42 weeks, stimulating intestinal peristalsis
2. Anal Sphincter Maturation: Relaxation occurs more readily with advancing gestation
3. Oligohydramnios: Placental ageing reduces amniotic fluid volume, concentrating any passed meconium into thick, tenacious material
4. Decreased Placental Reserve: Reduced capacity to tolerate labour stress increases hypoxic events

---

3. Pathophysiology

The "Triple Hit" Mechanism

MAS pathophysiology involves three simultaneous insults that synergistically cause respiratory failure. [7,14]

1. Mechanical Airway Obstruction

Inhaled meconium particles (size range 5-500 μm) lodge in airways at multiple levels: [14]

• Complete obstruction: Causes distal atelectasis and V/Q mismatch
• Partial obstruction (Ball-Valve Effect):
  • Air enters during inspiration when airways dilate
  • Air cannot exit during expiration when airways narrow
  • Progressive air trapping → hyperinflation → pneumothorax
• Anatomical predilection: Right lower lobe most commonly affected due to bronchial anatomy

Clinical Consequence: Air trapping occurs within hours. Pneumothorax risk peaks at 24-48 hours and affects 15-33% of ventilated infants. [10]

2. Chemical Pneumonitis

Meconium is a complex biological mixture that is highly irritating to pulmonary tissue: [14,15]

Composition of Meconium:

Inflammatory Cascade:

1. Immediate (0-6 hours): Meconium contact causes direct epithelial injury
2. Early inflammatory (6-24 hours):
   • Neutrophil chemotaxis (IL-8, complement C5a)
   • Cytokine release (IL-1β, IL-6, TNF-α)
   • Reactive oxygen species generation
3. Established inflammation (24-72 hours):
   • Pulmonary oedema (increased capillary permeability)
   • Alveolar haemorrhage (5-10% of cases)
   • Type II pneumocyte apoptosis

3. Surfactant Inactivation

Meconium components directly inhibit surfactant function through multiple mechanisms: [7,16]

1. Competitive displacement: Bile salts displace surfactant proteins SP-A and SP-B from the phospholipid monolayer
2. Physicochemical inhibition: Meconium components reduce surface tension-lowering capacity
3. Decreased production: Type II pneumocyte injury reduces new surfactant synthesis
4. Increased consumption: Inflammatory response accelerates surfactant degradation

Clinical Consequence: Alveolar collapse (atelectasis), decreased lung compliance, and impaired gas exchange. This is the rationale for exogenous surfactant therapy, which has been shown to reduce ECMO requirement (NNT = 6). [17]

Persistent Pulmonary Hypertension of the Newborn (PPHN)

PPHN complicates 15-20% of MAS cases and represents the primary cause of mortality. [8]

Pathogenesis:

Hypoxia + Acidosis + Pulmonary Vasoconstriction
           ↓
Pulmonary Vascular Resistance (PVR) ↑↑
           ↓
PVR > Systemic Vascular Resistance (SVR)
           ↓
Right-to-Left Shunting (via PDA and PFO)
           ↓
Systemic Hypoxemia (bypasses lungs)
           ↓
Further Hypoxia → Worsening Vasoconstriction
           ↓
"Death Spiral" of Progressive Hypoxic Respiratory Failure

Molecular Mechanisms:

• Endothelin-1: Potent vasoconstrictor elevated in MAS/PPHN
• Nitric Oxide (NO): Endogenous vasodilator production impaired
• Prostacyclin (PGI2): Reduced vasodilator prostaglandin
• Structural remodelling: Pulmonary arterial muscularization occurs with prolonged hypoxia

Infection Risk and Secondary Bacterial Pneumonia

Meconium is sterile but provides an excellent growth medium for bacteria. [18] There is also radiological and clinical overlap with congenital bacterial pneumonia:

• Primary concern: Group B Streptococcus (GBS), Escherichia coli, Listeria monocytogenes
• Secondary infection: Occurs at 5-7 days if meconium not cleared; E. coli most common
• Management implication: All MAS infants should receive empiric antibiotics (ampicillin + gentamicin) for 48-72 hours pending cultures

---

4. Clinical Presentation

Symptoms and Signs

Delivery Room Findings

Progressive Respiratory Distress Features

Red Flags and Warning Signs

[!CAUTION] Red Flag: Sudden Deterioration

• Sudden increase in oxygen requirement (e.g., 40% → 100%)
• Cardiovascular collapse (hypotension, tachycardia)
• Asymmetric chest movement or breath sounds Action: Suspect pneumothorax. Transilluminate immediately. Do not wait for X-ray if haemodynamically unstable. Needle thoracocentesis may be life-saving.

[!CAUTION]
Red Flag: Differential Cyanosis

• Pre-ductal SpO2 (right hand): 95%
• Post-ductal SpO2 (foot): 80-85%
• Difference > 10% indicates significant R→L ductal shunting Action: This is PPHN until proven otherwise. Obtain urgent echocardiogram. Consider inhaled nitric oxide. Avoid agitation.

[!CAUTION] Red Flag: Oxygenation Index Rising

• OI > 25 indicates severe disease
• OI > 40 indicates potential ECMO candidacy
• Formula: OI = (MAP × FiO2 × 100) ÷ PaO2 Action: Contact ECMO centre for discussion at OI > 25. Transfer at OI > 35-40 depending on trajectory.

The Clinical Phases of MAS

---

5. Clinical Examination

Systematic Assessment

Inspection

• General appearance: Meconium staining of skin, nails, umbilical cord (indicates prolonged exposure)
• Respiratory pattern: Tachypnoea, grunting, use of accessory muscles
• Chest shape: Barrel chest indicating hyperinflation (anteroposterior diameter increased)
• Colour: Central cyanosis versus peripheral cyanosis; differential cyanosis suggests PPHN

Auscultation

• Breath sounds: Coarse crackles bilaterally ("wet lungs"); may be diminished with significant air trapping
• Air entry: Asymmetry suggests atelectasis or pneumothorax
• Heart sounds: Loud P2 if PPHN present; murmur of tricuspid regurgitation in severe cases

Cardiovascular Assessment

• Heart rate and rhythm: Tachycardia common; arrhythmias suggest severe hypoxaemia
• Perfusion: Capillary refill time > 3 seconds indicates poor cardiac output (PPHN-related)
• Saturations: Pre-ductal and post-ductal measurements essential

Neurological Concerns

• Tone and activity: Hypotonia may indicate concurrent HIE
• Seizures: 20-30% of severe MAS cases develop seizures within 24 hours [19]
• Fontanelle: Assess for signs of raised intracranial pressure

---

6. Investigations

Diagnostic Algorithm

Neonate with MSAF + Respiratory Distress
              ↓
┌─────────────────────────────────────────┐
│ IMMEDIATE (Delivery Room/First Hour)   │
├─────────────────────────────────────────┤
│ • Pre/post-ductal SpO2                  │
│ • Blood glucose                         │
│ • Chest X-ray (portable)                │
│ • Blood gas (arterial or capillary)     │
└─────────────────────────────────────────┘
              ↓
┌─────────────────────────────────────────┐
│ WITHIN 4-6 HOURS                        │
├─────────────────────────────────────────┤
│ • Full blood count (infection markers)  │
│ • Blood culture                         │
│ • CRP/Procalcitonin                     │
│ • Coagulation screen (if DIC suspected) │
│ • Lactate                               │
└─────────────────────────────────────────┘
              ↓
┌─────────────────────────────────────────┐
│ IF PPHN SUSPECTED (SpO2 diff > 10%)      │
├─────────────────────────────────────────┤
│ • Echocardiogram (URGENT)               │
│ • Consider cranial USS if HIE concern   │
│ • Repeat blood gas after interventions  │
└─────────────────────────────────────────┘

Chest X-Ray Interpretation

The chest radiograph in MAS has characteristic findings reflecting the underlying pathophysiology: [20]

Classic "Salt and Pepper" Appearance:

Complications to Identify:

Blood Gas Interpretation

Oxygenation Index (OI) Calculation

The Oxygenation Index is the single most important number for assessing severity and guiding escalation: [9]

Formula:

OI = (Mean Airway Pressure × FiO2 × 100) ÷ PaO2 (in mmHg)

Echocardiography for PPHN

Echocardiography is essential for confirming PPHN and guiding treatment: [8]

Key Findings:

---

7. Management

Delivery Room Management (NRP 2020 Guidelines)

Current evidence does not support routine tracheal suctioning for meconium, even in non-vigorous infants. [6]

Algorithm for MSAF Delivery

Delivery through MSAF
          ↓
    Is infant vigorous?
   (HR > 100, good tone, 
    breathing/crying)
          ↓
    ┌─────┴─────┐
   YES          NO
    ↓            ↓
 Routine       Initial steps:
 care at       • Warm, dry, stimulate
 mother's      • Position airway
 side          • Clear secretions if needed
    ↓            ↓
                Reassess
                 ↓
              ┌──┴──┐
          Improving   Not improving
              ↓            ↓
          Continue    PPV with mask
          observation    ↓
                     If HR less than 60 after
                     30 sec effective PPV
                         ↓
                     Intubate for
                     ventilation
                     (NOT for suctioning)

Key Changes from Historical Practice:

The Golden Rule: "Ventilate the lungs first. A baby with bradycardia needs oxygen, not a perfectly clean airway."

Respiratory Support Escalation

Initial Stabilization

Conventional Mechanical Ventilation

Critical Principle: The key to MAS ventilation is long expiratory time (Te). Air trapping worsens with short Te. If auto-PEEP develops, reduce rate before increasing set PEEP. [10]

High-Frequency Oscillatory Ventilation (HFOV)

HFOV is superior to conventional ventilation for severe MAS because: [10]

• Small tidal volumes reduce barotrauma
• Constant distending pressure recruits atelectatic lung
• Oscillations "shake out" meconium particles
• Lower peak pressures reduce air leak risk

Initial HFOV Settings:

Surfactant Therapy

Exogenous surfactant replaces and overwhelms the inactivated endogenous surfactant. [17]

Evidence Base (Cochrane Review): [17]

• 4 RCTs, 326 infants
• Reduced ECMO requirement: RR 0.64 (95% CI 0.46-0.91); NNT = 6
• Reduced air leak: Trend toward reduction (not significant)
• Mortality: No significant difference (likely due to ECMO salvage)

Indications:

• MAS requiring mechanical ventilation with FiO2 > 0.5
• Oxygenation Index > 15

Administration:

Therapeutic Lung Lavage

Reserved for severe obstruction with visible meconium in airways: [17]

Current Recommendation: Bolus surfactant (200 mg/kg) preferred over lavage due to equivalent efficacy with lower procedural risk. [17]

Inhaled Nitric Oxide (iNO) for PPHN

iNO is a selective pulmonary vasodilator that reduces PVR without systemic hypotension. [8,21]

Mechanism: NO activates guanylyl cyclase → increased cGMP → pulmonary vascular smooth muscle relaxation

Indications:

• Confirmed PPHN on echocardiography
• OI ≥15-25 despite optimal ventilation
• Pre-ductal/post-ductal SpO2 difference > 10%

Administration:

Response Rates: 60-70% of PPHN patients respond to iNO with improved oxygenation. [21]

Non-responders: Consider:

• Suboptimal lung recruitment (increase MAP)
• Severe RV dysfunction (may benefit from milrinone)
• Structural heart disease (repeat echo)
• ECMO referral

Adjunctive Pulmonary Vasodilators

ECMO (Extracorporeal Membrane Oxygenation)

ECMO provides cardiopulmonary bypass allowing "lung rest" and recovery. [9]

ECMO Criteria

Indications:

• OI persistently > 40 despite maximal medical therapy
• Failure to respond to iNO
• Predicted mortality > 80% (based on OI trajectory)

Contraindications:

• Gestational age less than 34 weeks
• Birth weight less than 2.0 kg
• Irreversible brain injury (Grade IV IVH)
• Lethal congenital anomalies
• Active bleeding/uncontrollable coagulopathy
• Mechanical ventilation > 14 days (relative)

ECMO Types:

• VA-ECMO (Veno-Arterial): Preferred for MAS with cardiac dysfunction
  • Right internal jugular (drainage) → Right carotid (return)
  • Provides both cardiac and respiratory support
• VV-ECMO (Veno-Venous): If cardiac function preserved
  • Single dual-lumen catheter or two-site cannulation
  • Respiratory support only

Outcomes:

• MAS survival on ECMO: 94% (highest of all neonatal indications) [9]
• Duration: Typically 5-7 days
• Complications: Intracranial hemorrhage (5-10%), thrombosis, cannulation site issues

The ECMO Journey

Antibiotic Therapy

MAS is clinically and radiologically indistinguishable from bacterial pneumonia. Empiric antibiotics are standard. [18]

Stop Rule: If blood culture negative at 48 hours AND CRP normal/normalizing, discontinue antibiotics.

Supportive Care

---

8. Complications

Respiratory Complications

Cardiovascular Complications

Neurological Complications

Haematological Complications

---

9. Differential Diagnosis

Critical Differentiation: MAS vs GBS Pneumonia

These conditions are clinically and radiologically identical. Always treat for both until proven otherwise. [18]

---

10. Prognosis and Outcomes

Short-Term Outcomes

Long-Term Outcomes

Prognostic Factors

Follow-Up Schedule

---

11. Prevention

Primary Prevention

Secondary Prevention

---

12. Key Guidelines

1. Neonatal Resuscitation Program (NRP) 8th Edition (2020): Recommends against routine tracheal suctioning for MSAF deliveries, regardless of infant vigour. Focus on establishing ventilation. [6]

2. American Academy of Pediatrics (AAP): Clinical Report on Management of MAS emphasizes the "Triple Hit" pathophysiology and escalation pathway from conventional to high-frequency ventilation, surfactant, iNO, and ECMO. [1]

3. Extracorporeal Life Support Organization (ELSO): ECMO indications include OI > 40 or failure to respond to maximal medical therapy. MAS has the best neonatal ECMO outcomes. [9]

4. British Association of Perinatal Medicine (BAPM): Framework for use of inhaled nitric oxide in neonates. [21]

---

13. Viva Preparation

Opening Statement

"Meconium Aspiration Syndrome is a serious neonatal respiratory disorder occurring when infants born through meconium-stained amniotic fluid develop respiratory distress due to airway obstruction, chemical pneumonitis, and surfactant inactivation. It primarily affects term and post-term infants and is complicated by persistent pulmonary hypertension in 15-20% of cases, which is the main driver of mortality."

Common Viva Questions with Model Answers

Q: A baby is born at 42 weeks through thick meconium. The baby is floppy with HR 80. What is your immediate management?

"This is a non-vigorous infant born through meconium-stained amniotic fluid. According to current NRP 2020 guidelines, I would NOT routinely intubate for tracheal suctioning. My priorities are:

1. Initial steps: warm, dry, stimulate, position airway, clear secretions from mouth and nose
2. If no improvement after 30 seconds, initiate positive pressure ventilation
3. If HR remains below 60 after 30 seconds of effective PPV, then intubate for ventilation—not suctioning The heart rate is the priority. Delaying ventilation to suction has been shown to worsen outcomes."

Q: How does meconium cause lung injury?

"Meconium causes a 'Triple Hit' to the lungs:

1. Mechanical obstruction: Meconium particles cause partial obstruction with a ball-valve effect—air enters but cannot exit, causing hyperinflation and predisposing to pneumothorax
2. Chemical pneumonitis: Bile acids, pancreatic enzymes, and other components trigger an inflammatory cascade with cytokine release (IL-6, IL-8, TNF-alpha) causing pulmonary oedema and V/Q mismatch
3. Surfactant inactivation: Bile salts displace surfactant proteins from the phospholipid layer, causing alveolar collapse. This is why exogenous surfactant is effective."

Q: When would you start inhaled nitric oxide?

"I would start iNO for confirmed or strongly suspected PPHN with:

• Oxygenation Index ≥15-25 despite optimal ventilation
• Pre-ductal to post-ductal saturation difference > 10%
• Echocardiographic evidence of right-to-left shunting and elevated pulmonary pressures

I would start at 20 ppm and assess response within 30-60 minutes. Approximately 60-70% of infants respond. For non-responders, I would optimize lung recruitment, consider sildenafil, and discuss ECMO referral if OI approaches 40."

Q: What are the ECMO criteria for MAS?

"ECMO criteria include:

• Oxygenation Index persistently > 40 despite maximal medical therapy (optimal ventilation, surfactant, iNO, second-line vasodilators)
• Failure to respond to inhaled nitric oxide
• Predicted mortality > 80%

Contraindications include gestational age less than 34 weeks, birth weight less than 2 kg, irreversible brain injury (Grade IV IVH), lethal anomalies, or uncontrollable coagulopathy.

Importantly, MAS has the best neonatal ECMO survival rate at approximately 94%, so ECMO should not be delayed when indicated."

What Gets You Failed

❌ Recommending routine tracheal suctioning for meconium (outdated practice) ❌ Missing PPHN—not checking differential saturations ❌ Not knowing the Oxygenation Index formula ❌ Stating that amnioinfusion prevents MAS ❌ Forgetting to give antibiotics (cannot distinguish from GBS pneumonia) ❌ Not knowing when to refer for ECMO

Additional Viva Questions

Q: Describe your ventilation strategy for a baby with severe MAS and air trapping.

"The key principle in MAS ventilation is to allow adequate expiratory time to avoid worsening air trapping. My strategy would be:

1. Mode: Pressure-controlled SIMV for synchrony
2. Inspiratory time: Short (0.3-0.35s) to maximize expiratory time
3. Rate: Moderate (40-50/min); avoid rates > 60 which shorten Te
4. PEEP: Low-to-moderate (5-6 cmH2O); higher PEEP worsens air trapping
5. Watch for auto-PEEP: If chest doesn't return to baseline before next breath

If conventional ventilation fails (OI > 15-20), I would transition to HFOV, which uses very small tidal volumes at high frequency. HFOV provides more consistent mean airway pressure for recruitment while avoiding the high peak pressures that cause barotrauma."

Q: How do you differentiate MAS from congenital pneumonia?

"This is one of the most important clinical distinctions because the presentations are identical and both are life-threatening.

Clinically:

• MAS: Post-term, obvious MSAF, immediate distress from birth
• Pneumonia (GBS/Listeria): Maternal fever, prolonged rupture of membranes, GBS colonization, may have delayed onset (4-6 hours)

Investigations:

• CRP: Rises early (less than 6h) in bacterial infection; rises later (> 24h) in MAS
• Blood culture: Positive in bacterial pneumonia; negative in MAS
• CXR: Indistinguishable—patchy infiltrates in both

Management:

• Because we cannot reliably distinguish them at presentation, ALL babies with MAS should receive empiric antibiotics (ampicillin + gentamicin) for 48-72 hours pending culture results.
• If cultures negative and CRP normalizing at 48 hours, antibiotics can be stopped."

Q: What are the indications for therapeutic hypothermia in a baby with MAS?

"Therapeutic hypothermia is indicated if the baby has evidence of moderate-to-severe hypoxic-ischemic encephalopathy (HIE) in addition to MAS. The criteria include:

1. Gestational age: ≥35 weeks
2. Evidence of perinatal asphyxia:
   • pH less than 7.0 or BE < -16 on cord/early blood gas, OR
   • Apgar score ≤5 at 10 minutes, OR
   • Need for resuscitation at 10 minutes
3. Clinical encephalopathy:
   • Altered level of consciousness
   • Abnormal tone
   • Abnormal primitive reflexes
   • Seizures
4. Timing: Must be initiated within 6 hours of birth

MAS and HIE commonly coexist because meconium passage is often triggered by hypoxia. Up to 30% of severe MAS cases have concurrent HIE and may benefit from cooling."

Q: Discuss the evidence for surfactant in MAS.

"The evidence comes from the Cochrane review by El Shahed et al (2014), which included 4 RCTs and 326 infants.

Key findings:

• ECMO requirement: Significantly reduced with surfactant (RR 0.64; 95% CI 0.46-0.91). The NNT is 6—meaning we need to treat 6 babies with surfactant to prevent one ECMO case.
• Air leak: Trend toward reduction but not statistically significant
• Mortality: No significant difference, likely because ECMO salvages those who would otherwise die

Mechanism: Meconium inactivates endogenous surfactant through bile salt displacement and protein inhibition. Exogenous surfactant at high dose (200 mg/kg) can overwhelm this inhibition.

Indications in practice: MAS requiring mechanical ventilation with FiO2 > 0.5 or OI > 15. I would give early rather than late."

---

14. Delivery Room Team Roles

Team Composition for High-Risk MSAF Delivery

Pre-Delivery Brief Checklist

Equipment Check:

• Radiant warmer on and preheated
• Suction: 10-12 Fr catheter, wall suction at 80-100 mmHg
• Bag-mask ventilation: Correct size mask, oxygen connected
• Intubation equipment: Laryngoscope, 3.0-3.5 mm ETT, stylet
• Pulse oximeter with neonatal probe (right hand placement)
• Stethoscope
• Meconium aspirator (for ETT suction if needed)

Team Brief:

• "This is a [gestational age] pregnancy with thick meconium and [CTG findings]"
• "If the baby is vigorous, we provide routine care at mother's side"
• "If non-vigorous, we follow NRP algorithm—focusing on ventilation, not routine suctioning"
• "Does everyone have questions about their role?"

Immediate Post-Delivery Assessment

Vigour Assessment (within 30 seconds):

If ANY component is non-vigorous: Proceed to resuscitation.

---

15. Psychosocial Support

Family-Centred Care During NICU Admission

For Parents

The Traumatic Birth Experience:

• MAS often follows emergency deliveries with fetal distress
• Parents may have witnessed resuscitation efforts
• Rates of PTSD, anxiety, and depression are elevated in parents of NICU infants
• Early psychological support should be offered

Communication Principles:

• Update parents at least twice daily (more frequently if condition changing)
• Use consistent terminology across the team
• Avoid jargon; explain medical terms
• Allow time for questions and emotional processing
• Involve parents in decision-making where appropriate

Promoting Bonding:

• Encourage "hand hugs" (parents placing hands on baby through incubator)
• Kangaroo care when stable (may be limited initially due to equipment)
• Voice recognition—encourage parents to talk to baby
• Photographs for parents who cannot be present continuously
• Involve parents in cares when appropriate (nappy changes, mouth care)

Breastfeeding Support

• Maternal stress delays lactogenesis II (milk "coming in")
• Encourage pumping within 6 hours of birth
• Colostrum can be given via OG tube even if baby not feeding
• Lactation consultant referral early
• Reassure: most mothers can establish supply even with delayed start

For Siblings

• Age-appropriate explanation of what happened
• Facilitated visits to NICU if appropriate
• Play therapy resources for processing
• Maintain routines where possible

Psychological Support Resources

---

16. Discharge Planning

Discharge Readiness Criteria

Medical Criteria:

• Stable in room air for ≥48 hours (or home oxygen arranged if needed)
• Temperature stable in open cot
• Full oral feeds established (or NG feeding and parents trained)
• Weight stable or gaining
• No apnoeas or bradycardias for ≥5 days
• Completing any required antibiotic courses

Investigations Complete:

• Cranial ultrasound (if severe MAS, HIE, or ECMO)
• Hearing screening (especially if ECMO or aminoglycoside exposure)
• Any other clinically indicated investigations

Parent Education Completed:

• Infant CPR training
• Safe sleep education
• Warning signs to return to hospital
• Medication administration (if any)
• Equipment use (if home oxygen/monitors)

Follow-Up Arrangements

Red Flags for Parents to Seek Medical Attention

Return immediately if:

• Breathing fast or working hard to breathe
• Colour change (pale, blue, grey)
• Feeding poorly or refusing feeds
• Unusually sleepy or difficult to wake
• Fever (temperature > 38°C) or cold (temperature less than 36°C)
• Any concerns

---

17. Quality Metrics and Audit

Key Performance Indicators for MAS Management

Case Review Triggers

The following cases should trigger formal case review:

• Any MAS death
• Unplanned transfer to ECMO centre
• Pneumothorax requiring drainage
• Grade III-IV IVH
• Therapeutic hypothermia required
• Prolonged ventilation (> 14 days)

---

18. Parent Information

Frequently Asked Questions

Q: Did my baby poop because of stress?

A: Not always. In babies born after their due date, meconium passage can happen simply because the gut has matured. However, in some cases, if the baby experienced stress (like reduced oxygen), this can also trigger meconium passage. This is why we monitor closely for any signs that might indicate the baby experienced stress to the brain as well.

Q: Will my baby have asthma?

A: There is a slightly higher risk of wheezing and respiratory infections in the first few years, as the lungs heal from the inflammation. Most children grow out of these symptoms by school age. We will follow up with respiratory reviews to monitor this.

Q: Why is my baby on the "shaking machine" (oscillator)?

A: The oscillator (high-frequency ventilator) is gentler on your baby's lungs than a regular breathing machine. Instead of pushing big breaths in, it vibrates air in and out very quickly with tiny movements. This protects the delicate, inflamed lungs while still getting oxygen in and carbon dioxide out.

Q: What is the nitric oxide for?

A: Some babies with meconium aspiration develop high blood pressure in the lungs, which means blood bypasses the lungs and doesn't pick up enough oxygen. Inhaled nitric oxide is a special gas that relaxes the blood vessels in the lungs only, without affecting the rest of the body. It helps more blood flow through the lungs to pick up oxygen.

Q: What is ECMO?

A: ECMO stands for Extra-Corporeal Membrane Oxygenation. It's a machine that acts like an artificial heart and lung outside the body. We take blood out through a tube in a large blood vessel, add oxygen and remove carbon dioxide, then return it to the body. This lets your baby's lungs rest and heal. Babies with meconium aspiration who need ECMO have an excellent chance of survival—about 94%.

---

15. References

1. Wiswell TE, Gannon CM, Jacob J, et al. Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trial. Pediatrics. 2000;105(1 Pt 1):1-7. doi:10.1542/peds.105.1.1

2. Cleary GM, Wiswell TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome: an update. Pediatr Clin North Am. 1998;45(3):511-529. doi:10.1016/s0031-3955(05)70025-0

3. Dargaville PA, Copnell B; Australian and New Zealand Neonatal Network. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. Pediatrics. 2006;117(5):1712-1721. doi:10.1542/peds.2005-2215

4. Singh BS, Clark RH, Powers RJ, Spitzer AR. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. J Perinatol. 2009;29(7):497-503. doi:10.1038/jp.2008.241

5. Yoder BA, Kirsch EA, Barth WH, Gordon MC. Changing obstetric practices associated with decreasing incidence of meconium aspiration syndrome. Obstet Gynecol. 2002;99(5 Pt 1):731-739. doi:10.1016/s0029-7844(02)01968-3

6. Weiner GM, et al. Neonatal Resuscitation: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2):S524-S550. doi:10.1161/CIR.0000000000000902

7. Mokra D, Mokry J, Calkovska A. Mechanically ventilated meconium aspiration syndrome in rabbits: effects of surfactant, NO, and lung lavage. Pediatr Pulmonol. 2004;38(3):188-196. doi:10.1002/ppul.20089

8. Lakshminrusimha S, Keszler M. Persistent Pulmonary Hypertension of the Newborn. Neoreviews. 2015;16(12):e680-e692. doi:10.1542/neo.16-12-e680

9. Barbaro RP, Paden ML, Guner YS, et al. Pediatric Extracorporeal Life Support Organization Registry Report 2016. ASAIO J. 2017;63(4):456-463. doi:10.1097/MAT.0000000000000603

10. Goldsmith JP, Karotkin EH. Assisted Ventilation of the Neonate. 6th ed. Elsevier; 2016:369-380. doi:10.1016/B978-0-323-39006-4.00020-X

11. Beligere N, Rao R. Neurodevelopmental outcome of infants with meconium aspiration syndrome: report of a study and literature review. J Perinatol. 2008;28 Suppl 3:S93-S101. doi:10.1038/jp.2008.154

12. Usher RH, Boyd ME, McLean FH, Kramer MS. Assessment of fetal risk in postdate pregnancies. Am J Obstet Gynecol. 1988;158(2):259-264. doi:10.1016/0002-9378(88)90134-8

13. Fischer C, Rybakowski C, Ferdynus C, et al. A Population-Based Study of Meconium Aspiration Syndrome in Neonates Born between 37 and 43 Weeks of Gestation. Int J Pediatr. 2012;2012:321545. doi:10.1155/2012/321545

14. Zagariya A, Bhat R, Uhal B, Navale S, Freidine M, Vidyasagar D. Cell death and lung cell histology in meconium aspirated newborn rabbit lung. Eur J Pediatr. 2000;159(11):819-826. doi:10.1007/s004310000573

15. Tyler DC, Murphy J, Cheney FW. Mechanical and chemical damage to lung tissue caused by meconium aspiration. Pediatrics. 1978;62(4):454-459. doi:10.1542/peds.62.4.454

16. Moses D, Holm BA, Spitale P, Liu MY, Enhorning G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol. 1991;164(2):477-481. doi:10.1016/s0002-9378(11)80003-7

17. El Shahed AI, Dargaville PA, Ohlsson A, Soll R. Surfactant for meconium aspiration syndrome in term and late preterm infants. Cochrane Database Syst Rev. 2014;(12):CD002054. doi:10.1002/14651858.CD002054.pub3

18. Sherman TI, Greenspan JS, St Clair N, Touch SM, Shaffer TH. Optimizing the neonatal thermal environment. Neonatal Netw. 2006;25(4):251-260. doi:10.1891/0730-0832.25.4.251

19. Sehdev HM, Stamilio DM, Macones GA, Graham E, Morgan MA. Predictive factors for neonatal morbidity in neonates with an umbilical arterial cord pH less than 7.00. Am J Obstet Gynecol. 1997;177(5):1030-1034. doi:10.1016/s0002-9378(97)70008-5

20. Dargaville PA, Gerber A, Jober S, et al. Prediction of successful lavage response in meconium aspiration syndrome. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F201-F206. doi:10.1136/archdischild-2014-306655

21. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006;(4):CD000399. doi:10.1002/14651858.CD000399.pub2

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists for patient care decisions.